Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 915-152-1 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Acceptable, well documented publication which meets basic scientific principles (as the data is used in a read-across approach, a maximal reliability score of 2 was attributed).
Data source
Reference
- Reference Type:
- publication
- Title:
- Systemic lanthanum is excreted in the bile of rats
- Author:
- Damment S.J.P. and Pennick M.
- Year:
- 2 007
- Bibliographic source:
- Toxicology Letters 171: 69-77
Materials and methods
- Objective of study:
- toxicokinetics
- Principles of method if other than guideline:
- Lanthanum chloride was administered by intravenous injection to rats and the plasma lanthanum concentration as well as the excretion in faeces and urine were determined (three independent experiments).
Experiment 1: Male and female rats (N = 18 weight range 140 -192 g) received a single i.v. dose of 0.03 mg/kg of lanthanum chloride and lanthanum plasma levels were monitored at regular intervals up to 24 h after adminstration of the test substance.
Experiment 2: Male rats (N= 21 weight range 243 to 265 g) received a single i.v. dose of 0.3 mg/kg of lanthanum chloride and lanthanum plasma levels were determined at regular intervals up to 72 h post dose.
Experiment 3: Male rats (N = 12, weight range 189 to 207 g) received a single i.v. dose of either 0.3 mg/kg lanthanum chloride or saline. Urine and faeces samples were collected up to day 42 post dose.
Experiment 4: Male bile cannulated rats (N= 6 weight range 191 to 255 g) received 0.3 mg/kg of lanthanum chloride i.v. 24 h after the cannulation surgery. Bile, faeces and urine were collected at 24 h intervals for up to 5 days. - GLP compliance:
- not specified
Test material
- Reference substance name:
- Lanthanum chloride, anhydrous
- EC Number:
- 233-237-5
- EC Name:
- Lanthanum chloride, anhydrous
- Cas Number:
- 10099-58-8
- Molecular formula:
- Cl3La
- IUPAC Name:
- lanthanum trichloride
- Details on test material:
- - Name of test material (as cited in study report): Lanthanum chloride
- Analytical purity: no data
Constituent 1
- Radiolabelling:
- no
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River UK Ltd. (Margate, UK) or Harlan UK Ltd. (Bicester, UK).
- Weight at study initiation:
Experiment 1: 140-192 g
Experiment 2: 243 - 265 g (males only)
Experiment 3: 198 - 207 g (males only)
Experiment 4: 191 - 255 g (males only)
Administration / exposure
- Route of administration:
- intravenous
- Vehicle:
- other: sodium chloride 0.9% w/vsolution
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
Lanthanum chloride was formulated in sterile 0.9% (w/v) sodium chloride. - Duration and frequency of treatment / exposure:
- single dose
Experiment 1: 24 h study duration
Experiment 2: 72 h study duration
Experiment 3: 42 days study duration
Experiment 5: 5 days study duration
Doses / concentrations
- Remarks:
- Doses / Concentrations:
Experiment 1: 0.03 mg/kg lanthanum chloride (0.017 mg/kg elemental lanthanum)
Experiment 2, 3 and 4: 0.3 mg/kg lanthanum chloride (0.17 mg/kg elemental lanthanum)
- No. of animals per sex per dose / concentration:
- Experiment 1: two or three animals per sex, per time point (total number: n = 18)
Experiment 2: total number: n = 21 (only males)
Experiment 3: total number 12, 6 treated, 6 control (only males)
Experiment 4: total number 6 (only males) - Control animals:
- yes, concurrent vehicle
- Details on study design:
- Experiment 3: After injection rats were housed individually in metabolism cages to allow separate collection of 24 h urine and faeces samples.
Experiment 4: The bile duct was surgically cannulated in a similar group of male rats prior to drug administration. Rats were anaesthetized with isoflurane and a flexible plastic cannula inserted into the common bile duct. The cannula was exteriorized to allow free movement and complete bile collection. After a recovery period of 24 h, rats received a single dose of 0.3 mg/kg lanthanum chloride (0.17 mg/kg elemental lanthanum) by intravenous injection and were housed individually in metabolism cages for the separate collection of bile, faeces and urine at 24-h intervals for a period of 5
days. - Details on dosing and sampling:
- PHARMACOKINETIC STUDY (distribution, excretion after i.v. dosing, AUC determination
Eperiment 1 and 2
- Tissues and body fluids sampled: blood, plasma
- Time and frequency of plasma sampling: Experiment 1: pre-dose, 15 min., 1, 2, 4, 8 and 24 h after administration; Experiment 2: pre-dose, 5, 10, 20 and 40 min., 1, 2, 4, 8, 12, 18, 24, 48, 72 h
Sample PREPARATION and analysis Plasma Experiment 1 and 2
- Blood was centrifuged and plasma separated and diluted with tetramethyl ammonium hydroxide (TMAH) solution (1.25% [w/v] containing 0.1% [w/v] ethylenediaminetetraacetic acid diammonium salt [EDTA (NH4)2] as a lanthanum chelator). Lanthanum content was determined using an Agilent (Hewlett Packard) 4500 inductively coupled plasma (ICP)-mass spectrometer fitted with a Babington V-groove nebulizer and a glass spray chamber.
- The lower limit of quantification was 0.05 ng/mL.
Experiment 3 and 4
Experiment 3: Excreta samples were collected for the first 14 days, and then on days 21, 28, 35 and 42 post-dose.
Experiment 4: Bile, faeces and urine were collected at 24-h intervals for a period of 5 days.
Urine and bile samples were diluted in TMAH (tetramethyl ammonium hydroxide) solution; Lanthanum content was determined using an Agilent (Hewlett Packard) 4500 inductively coupled plasma (ICP)-mass spectrometer fitted with a Babington V-groove nebulizer and a glass spray chamber (Scott double pass cooled to 2°C). The lower limit of quantification was 0.05 ng/mL.
Faecal samples were quantitatively homogenized with distilled water, dried overnight at 105 ± 2 °C, acid-digested by heating with 2.0 mL nitric acid and 0.5 mL perchloric acid, and quantitatively resuspended in 1% nitric acid. Lanthanum content was determined using an Agilent 4500 ICP-mass spectrometer (lower limit of lanthanum quantification: 0.4 ng/mL). - Statistics:
- Pharmacokinetic parameters were derived from plasma lanthanum concentrations by visual inspection of the individual or mean plasma concentration curves or by non-compartmental analysis using WinNonlin® (Version 3.0, Pharsight Corporation, Mountain View, California).
The observed maximum plasma lanthanum concentration (Cmax) and the time post-dose at which Cmax occurred (Tmax) were determined by visual inspection of individual or mean plasma concentration versus time curves. The area under the plasma concentration versus time curves, calculated from time 0 to 24 h post-dose (AUC 0–24), and from time 0 to the last sample collection time (AUC last) were calculated using linear trapezoidal summation from time 0 to the appropriate time point. Total clearance (CL) following intravenous administration was calculated as Dose IV/AUC IV, and volume of distribution (Vz) was calculated as CL/k, where k was the terminal rate constant calculated following log-linear regression analysis of the linear phase of the concentration–time profile.
Results and discussion
- Preliminary studies:
- no data
Toxicokinetic / pharmacokinetic studies
- Details on absorption:
- Not appliable as this summary concerns only the i.v. part of the publication
- Details on distribution in tissues:
- Experiment 2:
Following intravenous injection of 0.3 mg/kg lanthanum chloride (the maximum tolerated intravenous dose established in previous studies), plasma lanthanum levels decreased rapidly from a peak of 3231±233 ng/mL measured at 5 min, to approximately 14% of Cmax by 2 h postdose. Thereafter, plasma concentrations declined at a slower rate and returned to pre-dose concentrations (3.08 ± 2.91 ng/mL) by 48 h.
The systemic clearance of lanthanum was relatively low: 0.66 mL/(min. kg) compared with a reported cardiac output of 160 mL/(min kg) and a hepatic plasma flow of 30 mL/(min kg) for male rats as reported in the literature. Combined with a Vz (volume of distribution) of 1.30 L/kg that exceeded total body water (0.7 L/kg), it can be suggested that lanthanum was distributed into tissues, from where it was eliminated at a slower rate. The whole blood to plasma lanthanum ratio based on AUC last was calculated as 0.55, indicating that very little lanthanum entered or was bound to red blood cells. In vitro plasma binding studies reported in the same paper showed a plasma protein binding of lanthanum of > 99.7% in both rat and human plasma.
- Details on excretion:
- Experiment 3: After a single i.v. dose of 0.3 mg/kg of lanthanum chloride 76.4 +- 5.69% of lanthanum was recovered over 42 days. 96.9 +- 0.5% of this dose was excreted in the faeces, most of it (87.7 +- 3.81%) in the first 14 days. Only 0.63 +- 0.45% was recovered in the faeces between day 35 and 42 after dosing. Only 1.94 +- 0.24% of the administered La was excreted in the urine within 42 d; 41.0 +- 1.98% of this amount was excreted in the urine in the first 24 h after dosing. The amounts of excreted La were corrected for background values of La excreted by control rats. The lanthanum content of the faeces of control rats was up to 40.5 +- 1.92 micro-g over 42 days (this would hav been equivalent to 48% of the dose in treated animals). The concentration of La in the urine of untreated controls was below the limit of quantification of 0.4 ng/mL. The relatively low total recovery is attributed in part by the authors to the underestimation of fecal excretion due to the high background levels in faeces. Another reason may be a tissue distribution e.g. into bone tissue at the high i.v. dose that were associated with non-linar pharmacokinetics and are suggestive of a saturation of plasma binding and/or clearance mechanisms. An internal dose of 40 micro-g of La for a 250 g rat may have exceeded a calculated plasma binding capacity of 15 micro-g of La per 50 g rat as stated by the authors.
Experiment 4:
In bile duct cannulated rats receiving an i.v. dose of 0.3 mg/kg bw the recovery was very low. Only 12 +- 3.29% of the administered dose was recovered over the 5 day collection period. Of the recovered amoutn 85.6 +- 2.97% was excreted in the bile, 5.96 +- 3.41% was found in the faeces and 5.74 +- 0.91% in urine. The reduced recovery in bile cannulated rats is attributed by the authors to the bile cannulation surgery and/or the anaesthesia that could have caused a transient fall in bile flow.
Following intravenous administration of lanthanum chloride, biliary excretion was the predominant route of elimination, with 85.6% of recovered lanthanum collected from bile over a period of 5 days. However, a significant proportion (5.96%) of the element was recovered in the faeces of bile-duct cannulated animals, suggesting that lanthanum may also be eliminated directly across the gut wall.
Toxicokinetic parametersopen allclose all
- Test no.:
- #2
- Toxicokinetic parameters:
- Tmax: 5 min
- Test no.:
- #2
- Toxicokinetic parameters:
- Cmax: 3231+/-233 ng/mL
- Test no.:
- #2
- Toxicokinetic parameters:
- C(time): 48 h: 3.08 +/- 2.91 ng/mL
- Test no.:
- #1
- Toxicokinetic parameters:
- AUC: 45.07 ng*h/mL
Metabolite characterisation studies
- Metabolites identified:
- not measured
- Details on metabolites:
- For inorganic compounds metabolism is not relevant
Any other information on results incl. tables
Experiment 2:
After i.v. administration of 0.3 mg/kg lanthanum chloride a peak plasma concentration was reached 5 min after administration with 3231 +/- 233 ng/mL. This declined to approximately 14% of the value within 2 h. Thereafter plasma concentrations declined at a slower rate. They returned to pre-dose levels (3.08 +/- 2.91 ng/mL) after 48 h.
Experiment 1:
The i.v. AUC was calculated after administration of a lower dose of lanthanum chloride of 0.03 mg/kg equivalent to 0.017 mgLa/kg. The AUC(0 -24 h) was 45.07 ng h/mL.
Experiment 3:
Excretion of La after a single i.v. administration of 0.5 mg/kg lanthanum chloride within 42 days:
% of administered dose (mean +/- standard error of mean (S.E.M)), N = 6
Faeces: 74.1 +/- 5.82
Urine: 1.94 +/- 0.24
Cage wash: 0.31 +/- 0.04
Total: 76.4 +/- 5.69
% of recovered dose (mean +/- S.E.M.), N = 6
Faeces: 96.9 +/- 0.50
Urine: 2.66 +/- 0.49
Cage wash: 0.41 +/- 0.05
Total: 100
Experiment 4:
Recovery of lanthanum 5 days after administration of a single i.v. dose of 0.3 mg/kg lanthanum chloride
% of administered dose (mean +/- S.E.M.) N = 6
Bile: 10.0 +/- 2.46
Feaces: 1.16 +/- 0.72
Urine: 0.60 +/- 0.11
Cage wash: 0.29 +/- 0.10
Total: 12.0 +/- 3.29
% of recovered dose (mean +/- S.E.M.) N = 6
Bile: 85.6 +/- 2.97
Faeces: 5.96 +/- 3.41
Urine: 5.74 +/- 0.91
Cage wash: 2.73 +/- 0.92
Total: 100
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
